Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen, Cytokinetics heart failure drug succeeds in mid-stage study

[Reuters] – Amgen Inc and Cytokinetics Inc said on Tuesday their experimental drug for chronic heart failure showed significant improvement in cardiac function in the second part of a mid-stage study. The 448 . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen, Cytokinetics heart failure drug succeeds in mid-stage study Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s leukemia drug gets conditional European approval Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215 Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA panel backs Amgen’s cholesterol drug for high-risk patients